Gwendolyn Wu
Senior Reporter | LinkedInGwendolyn Wu is a senior reporter at BioPharma Dive covering biotech startups, venture capital, IPOs and the ecosystem that supports them. She was selected as the 2024 McAllister Editorial Fellow by SIIA in recognition for her work on a series of stories examining the world’s first CRISPR medicine. Previously, she authored Bay Briefing, the San Francisco Chronicle’s flagship weekday newsletter, and covered COVID-19 and the business of healthcare for the Houston Chronicle. Outside of the newsroom, Gwendolyn teaches at the California Scholastic Press Association summer workshop for high school journalists, and has led student and early career programs for the Asian American Journalists Association. She has degrees in history and sociology from the University of California at Santa Barbara.
488 articles by Gwendolyn Wu
-
Windward prices $175M IPO to advance China-licensed lung drugs
Nov. 12, 2026 -
London biotech Oyster harvests $60M for tau-targeting brain drugs
Nov. 10, 2026 -
BIO unveils plan for US to remain biotech’s ‘global leader’
Nov. 10, 2026 -
T-Therapeutics reloads with a $133M megaround for bispecifics
Nov. 5, 2026 -
Alethio raises $90M to target rare blood cancers
Nov. 5, 2026 -
With Setara, the team behind Actio opens its second act
Oct. 30, 2026 -
Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’s
Oct. 29, 2026 -
Flagship blends three biotech startups to form Etcelera
Oct. 29, 2026 -
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
Oct. 27, 2026 -
Corxel, an obesity drugmaker, to go public via SPAC deal
Oct. 26, 2026 -
Star adds $200M after spinout successes
Oct. 23, 2026 -
Protein degrader specialist Lycia prices $318M IPO
Oct. 22, 2026 -
Iambic, an AI drug discovery specialist, banks $150M in an IPO
Oct. 14, 2026 -
This week in charts: What’s driving biotech’s recent pullback?
Oct. 9, 2026 -
TRex Bio prices $117M IPO to support immune drug work
Oct. 9, 2026 -
Forbion, a prominent biotech investor, raises $2.6B for a pair of venture funds
Oct. 6, 2026 -
Novartis wagers almost $8B on a Chinese biotech’s RNA drugs
Oct. 2, 2026 -
Lilly, Foghorn part ways; Wave’s FDA-approved plans
Oct. 1, 2026 -
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Sept. 29, 2026 -
ai3Bio, built from two biotechs, pursues a different path to an ‘immune reset’
Sept. 29, 2026 -
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
Sept. 28, 2026 -
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
Sept. 25, 2026 -
RNAi drug specialist ADARx raises $446M IPO
Sept. 24, 2026 -
Enveda, an AI drugmaker, banks $311M in venture funding
Sept. 23, 2026 -
Amgen reports a Phase 3 win with Sjögren’s drug candidate
Sept. 22, 2026
